|
gptkbp:instanceOf
|
gptkb:brand
gptkb:drug
|
|
gptkbp:activeIngredient
|
niraparib
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2017
|
|
gptkbp:ATCCode
|
L01XX54
|
|
gptkbp:contraindication
|
hypersensitivity to niraparib
|
|
gptkbp:drugClass
|
antineoplastic agent
|
|
gptkbp:form
|
gptkb:tablet
capsule
100 mg
200 mg
300 mg
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ZEJULA
|
|
gptkbp:indication
|
gptkb:cancer
gptkb:fallopian_tube_cancer
primary peritoneal cancer
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Tesaro
GlaxoSmithKline
|
|
gptkbp:marketingAuthorizationHolder
|
GlaxoSmithKline
|
|
gptkbp:mechanismOfAction
|
PARP inhibitor
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:prescribes
|
maintenance treatment
platinum-sensitive ovarian cancer
recurrent ovarian cancer
|
|
gptkbp:prescriptionStatus
|
Rx only
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
constipation
fatigue
hypertension
insomnia
thrombocytopenia
|
|
gptkbp:website
|
https://www.zejula.com/
|
|
gptkbp:bfsParent
|
gptkb:Zai_Lab
|
|
gptkbp:bfsLayer
|
7
|